DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03280056 (ClinicalTrials.gov)	August 28, 2017	29/8/2017	Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients	A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALS	Amyotrophic Lateral Sclerosis (ALS)	Biological: NurOwn® (MSC-NTF cells);Other: Placebo	Brainstorm-Cell Therapeutics	California Institute for Regenerative Medicine (CIRM)	Active, not recruiting	18 Years	60 Years	All	261	Phase 3	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03280056
(ClinicalTrials.gov)

August 28, 2017

29/8/2017

Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients

A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALS

Amyotrophic Lateral Sclerosis (ALS)

Biological: NurOwn® (MSC-NTF cells);Other: Placebo

Brainstorm-Cell Therapeutics

California Institute for Regenerative Medicine (CIRM)

Active, not recruiting

18 Years

60 Years

All

261

Phase 3

United States